Literature DB >> 17266522

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Zoe E Barter1, Martin K Bayliss, Philip H Beaune, Alan R Boobis, David J Carlile, Robert J Edwards, J Brian Houston, Brian G Lake, John C Lipscomb, Olavi R Pelkonen, Geoffrey T Tucker, Amin Rostami-Hodjegan.   

Abstract

Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity (HPGL) per gram of liver, generally with no consideration of the extent of their inter-individual variability. We have collated and analysed data from a number of sources, to provide weighted meangeo values of human MPPGL and HPGL of 32 mg g-1 (95% Confidence Interval (CI); 29-34 mg.g-1) and 99x10(6) cells.g-1 (95% CI; 74-131 mg.g-1), respectively. Although inter-individual variability in values of MPPGL and HPGL was statistically significant, gender, smoking or alcohol consumption could not be detected as significant covariates by multiple linear regression. However, there was a weak but statistically significant inverse relationship between age and both MPPGL and HPGL. These findings indicate the importance of considering differences between study populations when forecasting in vivo pharmacokinetic behaviour. Typical clinical pharmacology studies, particularly in early drug development, use young, fit, healthy male subjects of around 30 years of age. In contrast, the average age of patients for many diseases is about 60 years of age. The relationship between age and MPPGL observed in this study estimates values of 40 mg.g-1 for a 30 year old individual and 31 mg.g-1 for a 60 year old individual. Investigators may wish to consider the reported covariates in the selection of scaling factors appropriate for the population in which estimates of clearance are being predicted. Further studies are required to clarify the influence of age (especially in paediatric subjects), donor source and ethnicity on values of MPPGL and HPGL. In the meantime, we recommend that the estimates (and their variances) from the current meta-analysis be used when predicting in vivo kinetic parameters from in vitro data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266522     DOI: 10.2174/138920007779315053

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  107 in total

1.  Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Authors:  Robert J Foxenberg; Corie A Ellison; James B Knaak; Changxing Ma; James R Olson
Journal:  Toxicology       Date:  2011-04-13       Impact factor: 4.221

2.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

3.  Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Authors:  David Hallifax; Joanne A Foster; J Brian Houston
Journal:  Pharm Res       Date:  2010-07-27       Impact factor: 4.200

4.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

5.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

6.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 7.  Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics.

Authors:  Matteo Di Nardo; Enno Diederick Wildschut
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

8.  Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.

Authors:  Ling Song; Yi Zhang; Ji Jiang; Shuang Ren; Li Chen; Dongyang Liu; Xijing Chen; Pei Hu
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

Review 9.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

10.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.